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Active metabolites of some antipsychotic drugs exhibit pharmacodynamic and pharmaco-
kinetic properties that may be similar to or differ from the original compound and that can
be translated by a different profile of responses and interactions to clinical level. Some of
these antipsychotics’ active metabolites might participate in mechanisms of antidepressant
activity, as m-chlorophenylpiperazine (aripiprazole), 9-OH-risperidone and norquetiapine.
Norquetiapine exhibits distinct pharmacological activity from quetiapine and plays a fun-
damental role in its antidepressant efficacy. In this review, we analyze the differential
pharmacological aspects between quetiapine and norquetiapine, both from the pharmaco-
kinetic and pharmacodynamic perspectives (affinity for dopaminergic, noradrenegic, and/or
serotonergic receptors, etc.), as well as differential neuroprotective role.The pharmacolog-
ical differences between the two drugs could explain the differential clinical effect, as well
as some differences in tolerability profile and drug interactions. The available data are suf-
ficient to arrive at the conclusion that antidepressant activity of quetiapine is mediated, at
least in part, by the active metabolite norquetiapine, which selectively inhibits noradrena-
line reuptake, is a partial 5-HT1A receptor agonist, and acts as an antagonist at presynaptic
α2, 5-HT2C, and 5-HT7 receptors.
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INTRODUCTION
The body treats drugs as foreign, or xenobiotic, substances, so it
tends to metabolize them to facilitate elimination. Usually, the
products of biotransformation are referred to as metabolites and
tend to be more water soluble than the original molecule so the
kidneys can more easily eliminate them (1, 2).
Usually, biotransformation produces chemically stable metabo-
lites that are neither pharmacologically nor toxicologically active.
In some cases, though, chemically reactive metabolites are gen-
erated and may be toxic. In addition, the reactions involved in
biotransformation may produce chemically stable and pharmaco-
logically active metabolites, termed “active metabolites” (3); those
will be the primary focus of this article.
Active metabolites exhibit pharmacodynamic and pharmaco-
kinetic properties that may be similar to or differ from the original
compound. In either case, they alter its activities and play a role in
its end result. In fact, the presence of active metabolites is akin to
polytherapy (2–4). Many medications give way to active metabo-
lites. They are only considered clinically relevant when this occurs
in high enough quantities to have a pharmacological impact, are at
least as active as the original compound, or exist in specific tissues,
like the brain (1, 2).
An active metabolite can be entirely or only partially respon-
sible for a drug’s therapeutic effect. Others may be pharmaco-
logically active in a way not related to the original molecule’s
main activity. Sometimes, a metabolite reverses or deactivates
the original molecule’s pharmacological activity (3). It is widely
believed that many psychoactive drugs’ effects are the result not
only of the original molecule, but its active metabolites. Moreover,
some drugs are inactive per se, and must be biotransformed in the
body to become pharmacologically active; these have been called
prodrugs.
At times, when an active metabolite improves the original
compound’s pharmacodynamic, pharmacokinetic, or toxicolog-
ical properties, it gets commercialized. Examples of this in psy-
chopharmacology include desipramine (desmethyl imipramine),
derivatives of the antidepressant imipramine, mesoridazine and
paliperidone, derivatives of the antipsychotics thioridazine and
risperidone, and oxazepam, diazepam’s metabolite (1, 3).
ACTIVE METABOLITES OF ANTIDEPRESSANT DRUGS
Antidepressants are a wide and varied group of drugs involving
many active metabolites. Some such metabolites have even been
commercialized as active agents in their own right. Table 1 presents
the major known active metabolites and their corresponding
antidepressants.
Nortriptyline is an active metabolite in amitriptyline and fea-
tures distinctly potent inhibition of monoamine transporters,
noradrenaline (NET), and serotonin (SERT) beyond that of its
parent compound. Thus, while amitriptyline inhibits both trans-
porters, its metabolite, nortriptyline, acts primarily as an inhibitor
of NET reuptake (5). In turn, 10-OH-nortriptyline, considered an
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Table 1 | Active metabolites of psychotropic drugs with antidepressants properties.
Parent drug Active metabolite Reference
ANTIDEPRESSANTS
Amitriptyline Nortriptyline* Owens et al. (5)
Nortriptyline 10-OH-Nortriptyline Nordin and Bertilsson (6)
Imipramine Desimipramine* Owens et al. (5)
Desimipramine Desmethyl desimipramine Deupree et al. (7)
Trimipramine Desmethyl trimipramine, 2-OH-Trimipramine, Trimipramine N -oxyde Haenisch et al. (8)
Clomipramine Desmethyl clomipramine# Tekes et al. (2)
Doxepin Desmethyl doxepin Tekes et al. (2)
Mianserine Desmethyl mianserine Kang et al. (9)
Mirtazapine Desmethyl mirtazapine Sitzen and Zivkov (4), Zivkov et al. (72)
Maprotiline Desmethyl maprotiline Wille et al. (1)
Trazodone m-Chlorophenylpiperazine Wille et al. (1)
Citalopram Desmethyl citalopram, Didesmethyl citalopram Tatsumi et al. (12), Popik (13), Milne and Goa (14), Caccia (73)
Escitalopram Desmethyl citalopram, Didesmethyl citalopram Tatsumi et al. (12)
Fluoxetine Desmethyl fluoxetine Owens et al. (5), Wong et al. (16)
Fluvoxamine Fluvoxamine acid Benfield and Ward (15), Caccia (73)
Sertraline Desmethyl sertraline Fuller et al. (11), Caccia (73)
venlafaxine N -Desmetil venlafaxine* Owens et al. (5), Muth et al. (20), Caccia (73)
Atomoxetine 4-Hydroxy atomoxetine Tekes et al. (2)
ANTIPSYCHOTICS
Aripiprazole m-Chlorophenylpiperazine Caccia (33)
Risperidone 9-OH-Risperidone *# Yang and Liang (38)
Quetiapine Norquetitapine Jensen et al. (49)
*Marketed as individual drug; #suspected activity.
active metabolite of nortriptyline, is a stronger NET inhibitor and
is less anticholinergic (6).
Desipramine is an active metabolite in imipramine, which
inhibits reuptake of NET and SERT; the metabolite features almost
selective NET inhibition. Desipramine and nortriptyline, in fact,
are the strongest NET reuptake inhibitors of the tricyclic anti-
depressants commercially available (5). Desipramine, too, is con-
verted into an active metabolite, desmethyl desipramine, which
has more affinity for SERT than for NET. This metabolite reduces
desipramine’s selectivity and adds to its overall antidepressant
effect (7).
Trimipramine also involves several pharmacologically active
metabolites. One is desmethyl trimipramine, which inhibits NET
and SERT transporters as strongly as its parent compound. How-
ever, 2-OH-trimipramine is weaker and trimipramine-N-oxide
preferentially inhibits SERT (8).
Other tricyclic antidepressants have active metabolites, but
their differential profiles relative to their parent compounds have
yet to be clearly elucidated. However, clomipramine is known to
give way to desmethyl clomipramine, and doxepin to the metabo-
lite desmethyl doxepin (2). Mianserin is demethylated to pro-
duce an active metabolite, N -desmethyl mianserin, whose longer
half-life increases the effect of mianserin (9).
Mirtazapine undergoes extensive metabolism during its
first pass through the liver, the major metabolic path-
ways in humans being N-demethylation, N-oxidation, and
8-hydroxylation, followed by conjugation. The demethylated
metabolite, normirtazapine, remains pharmacologically active,
but is three to four times less active than mirtazapine (4, 10).
Among selective serotonin reuptake inhibitors (SSRIs), citalo-
pram, fluoxetine, and sertraline are initially demethylated, generat-
ing desmethyl citalopram, norfluoxetine, and norsertraline, which
also inhibit SERT (11). Norcitalopram’s steady state plasma con-
centration approaches nearly 40% of citalopram’s, and it actively
inhibits SERT three to eight times less than citalopram (12, 13).
What is more, norcitalopram is converted into desmethyl citalo-
pram, which acts as a weak SERT reuptake inhibitor (4, 14).
Fluvoxamine is metabolized into multiple metabolites and the car-
boxylic acid derived from it has been shown to inhibit SERT weakly
compared to the parent compound (4, 15).
Fluoxetine is metabolized through N-demethylation into its
major active metabolite, norfluoxetine, which is comparable to
fluoxetine, from pharmacological perspective (5, 16). However,
norfluoxetine easily permeates the blood-brain barrier, reaches
higher plasma concentrations,and has a higher half-life than fluox-
etine (17, 18). In patients suffering from depression, norfluoxetine
reaches concentrations comparable or even higher than fluoxetine
(19), so it likely contributes considerably to the drug’s major SERT
inhibition, therapeutic effectiveness, and adverse effects (4).
Sertraline gives way to a demethylated metabolite called
desmethyl sertraline, which is a weaker SERT reuptake inhibitor
than sertraline in vivo. However, it may contribute to the prolonged
SERT transporter inhibition achieved by administering sertraline;
laboratory research has shown this to be more the case for mice
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than for rats. Nevertheless, it remains unclear how much norsertra-
line boosts the original compound’s therapeutic activity in humans
(4, 11).
Venlafaxine is a dual uptake inhibitor of SERT and NET. In
humans, most venlafaxine metabolism, almost 60%, takes place
through O-demethylation. Other minor metabolic routes include
N-demethylation, which produces N -desmethyl venlafaxine. O-
desmethyl venlafaxine exhibits similar pharmacological activity to
that of its parent compound, both in vitro and in vivo. The deriva-
tive N -desmethyl is also active, but has less capacity for SERT and
NET reuptake inhibition than venlafaxine does (4, 5, 20).
Atomoxetine is a selective NET reuptake inhibitor employed in
the treatment of attention deficit hyperactivity disorder (ADHD).
It generates a series of oxidative metabolites. Of those, 4-hydroxy-
atomoxetine stands out because it blocks NET with demonstrably
similar ability to atomoxetine. Atomoxetine’s remaining oxidative
metabolites, including N -desmethyl atomoxetine, all seem to be
pharmacologically inactive (21).
ACTIVE METABOLITES OF ATYPICAL ANTIPSYCHOTIC
DRUGS WITH ANTIDEPRESSANT ACTIVITY
Antipsychotics have a long history of effectiveness at treating
depressive profiles. In 1954, Kielhoz suggested chlorpromazine was
effective at treating depressive and manic episodes. Then Nahunek
et al. (22) reported that the first atypical antipsychotic, clozapine,
effectively treated endogenous depression. Today, atypical antipsy-
chotics are recognized as effective at treating bipolar depression
(23, 24), but in unipolar depression profiles, its efficacy has been
mainly shown as a combined, or adjunctive, treatment in resis-
tant profiles, an indication for which certain antipsychotics have
received official approval (25, 26). The question this article aims
to address is whether any of these antipsychotics’ active metabo-
lites (see Tables 1 and 2) might participate in mechanisms of
antidepressant activity.
Olanzapine, coupled with fluoxetine, was the first case of an
atypical antipsychotic drug showing greater efficacy than each
active principle separately (26, 27). Olanzapine produces various
metabolites, of which conjugated 10-N -glucuronide has notewor-
thy applications in humans. Other minor metabolites include N -
desmethyl olanzapine, 4-N-oxide-olanzapine, 2-hydroxymethyl
olanzapine, and 4-N -glucuronide. It is noteworthy that both
in vitro and in vivo, its primary metabolite, 10-N -glucuronide, is
inactive. Of the three remaining, minor metabolites,N -desmethyl
olanzapine and 2-hydroxymethylolanzapine display similar activ-
ity in vitro as their parent compound, while the rest are inactive or
nearly so. These data indicate that all of olanzapine’s metabolites
are less active than it, so their activity probably does not contribute
to its pharmacological profile (28).
Of the available atypical antipsychotics, aripiprazole has proven
effective as adjunctive treatment for major depression when it
is resistant to treatment with antidepressants (29, 30). FDA has
officially approved this indication. Aripiprazole’s antidepressant
action may be due, first, to its role as a partial agonist of D2, D3,
and 5-HT1A receptors, and second, to its ability to block 5-HT2
receptors (29). It is a piperazine derivative and may undergo an
array of metabolic processes, depending on the species. Dehydro-
aripiprazole is aripiprazole’s major metabolite in humans and
exhibits a similar pattern of activity at the D2 receptor (31).
Dehydro-aripiprazole has a longer half-life than the original com-
pound (32), suggesting it may contribute to its pharmacological
efficacy. One of its metabolites, 2-3-dichlorophenylpiperazine,
is an analog of m-Chlorophenylpiperazine (mCPP), an active
metabolite of trazodone and nefazodone. This metabolite reaches
a concentration in the brain 7% that of aripiprazole, so it could
contribute only partially to that particular atypical antipsychotic’s
antidepressant effect (33).
Risperidone has shown its effectiveness as adjunctive ther-
apy, especially in conjunction with SSRIs, in patients with
major depression (26). It is metabolized mainly by CYP450-
2D6 (CYP2D6), generating 9-OH-risperidone, or paliperidone,
through hydroxylation. When risperidone is administered, its
pharmacological effects are due to the original molecule as well
as its active metabolite. Considering that many patients who take
risperidone orally exhibit plasma levels of 9-OH-risperidone 5–10
times higher than risperidone (34), we consider the metabolite to
play an important role in the antipsychotic’s antidepressant effect
(Table 2) (35). In fact, extended-release paliperidone, whether
taken orally (36) or as an injection (37), has proven effective
in treating schizoaffective disorder, a profile marked by a set of
schizophrenia symptoms in addition to major depressive disorder.
According to these clinical data, paliperidone seems to behave like a
metabolite of risperidone and to have antidepressant activity. Nev-
ertheless, to date, paliperidone has never been studied in the treat-
ment of major depression, as monotherapy or adjunctive therapy.
Yang and Liang (38) did, however, report one case where a patient
with treatment-resistant depression was successfully treated with
paliperidone as adjunctive therapy.
With regard to quetiapine, this particular atypical antipsychotic
drug is extensively metabolized in the liver, where many of its
metabolites are produced. Its most important metabolite is N -
desalkyl quetiapine, also known as norquetiapine, which exhibits
distinct pharmacological activity from quetiapine and plays a fun-
damental role in its antidepressant efficacy. This article will explore
norquetiapine in depth in a special section below.
NORQUETIAPINE: ACTIVE METABOLITE OF QUETIAPINE
WITH ANTIDEPRESSANT ACTIVITY
The efficacy of quetiapine in treating psychotic disorders, both
schizophrenia and mania, as well as mood disorders and anxiety
disorders, leads us to view it as a multifunctional psychoactive
drug. Its broad spectrum of efficacy is likely due to its ability to
modify systems of dopaminergic, noradrenergic, and serotonergic
neurotransmission. Its effects appear to be mediated by the actions
of both quetiapine and norquetiapine.
Quetiapine is a dibenzothiazepine derivative available in
two different pharmaceutical forms: immediate-release (IR) and
extended-release (XR) (39). Both forms are metabolized exten-
sively by the liver into various metabolites, with only 1% elimi-
nated unaltered, in this case in urine (40).
N -desalkyl quetiapine, also known as norquetiapine, is queti-
apine’s key metabolite and is produced by the action of isoenzyme
CYP3A4 in cytochrome P450. No genetic polymorphisms affect
CYP3A4, so variations in quetiapine metabolism based on race or
genetics are unlikely. However, there may be interaction at the level
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Table 2 | Pharmacodynamic properties of quetiapina, risperidone, and their active metabolites (norquetiapine and paliperidone).
Receptors Quetiapine* Norquetiapine* Risperidone** 9-OH-risperidone (paliperidone)**
D2 245 196 4.9 9.4
5-HT2A 100 48 0.17 1.9
5-HT2C 2502 107 12 48
5-HT1A 432 45 427 640
5-HT7 307 76 – –
H1 11 3.5 5.2 5.6
Alpha-1 22 144 5 2.5
Alpha-2 3630 237 151 4.7
NET >10000 58 – –
Data are in Ki (nanomoles).
NET (norepinephrine transporter).
*Jensen et al. (49).
**PDPS Ki database: http:// pdsp.med.unc.edu/ pdsp.php).
of this isoenzyme with some inductors (carbamazepine, pheny-
toin) that increase the proportion of norquetiapine, or with potent
enzyme inhibitors (ketoconazole, itraconazole, erythromycin, and
fluvoxamine) that slow its production (41, 42). On another note,
there is more pharmacokinetic variability among older adults and
patients with concomitant medications in the case of quetiap-
ine than norquetiapine; norquetiapine levels are more stable (43).
CYP2D6 also contributes to quetiapine metabolism, though to
a lesser extent. This creates small quantities of 7-hydroxy que-
tiapine (44), whose activity has not yet been specifically deter-
mined. In addition, this isoenzyme metabolizes norquetiapine
into 7-hydroxy-desalkyl-quetiapine, which is pharmacologically
active (45).
According to Mauri et al. (46), quetiapine’s plasma concentra-
tions do not seem sufficiently high to explain its action at receptors
or its clinical effects, suggesting that active metabolites participate
in its pharmacodynamics. However, the plasma concentrations
of CNS drugs is a poor predictor of central activity because
numerous other factors influence target engagement, including
blood/brain barrier penetration, CNS accumulation, and receptor
association/dissociation kinetics.
PHARMACODYNAMIC PROFILE OF NORQUETIAPINE VS.
QUETIAPINE
Norquetiapine and quetiapine interact with the dopaminergic,
noradrenergic, and serotonergic systems, but differ qualitatively
and quantitatively in their respective abilities to alter those systems’
functioning. As with other atypical antipsychotics, quetiapine
can block 5-HT2A receptors with greater affinity than D2 recep-
tors, which may explain its antipsychotic properties and lower
propensity to cause extrapyramidal symptoms and hyperprolacti-
naemia (40). Furthermore, quetiapine shows affinity for different
serotonergic and noradrenergic receptors, which may contribute
to its antidepressant and anxiolytic effects (47). Also, its active
metabolite, norquetiapine, is highly important in that in addi-
tion to inhibiting NET reuptake, it shows affinity for several SERT
receptors (41, 42).
An overall picture of the receptor profiles of quetiapine and
norquetiapine appears in the Figure 1.
FIGURE 1 | Binding affinities of quetiapine (white bars) and its
metabolite N -Desalkylquetiapine (dark bars) at the tested panel of
brain receptors neurotransmitter transporters (K i in nanomoles on a
logarithmic scale). Modified to Jensen et al. (49).
DOPAMINERGIC FUNCTIONING
D2 receptor occupancy in the limbic system is the primary mecha-
nism for bringing about antipsychotic effects. Quetiapine and nor-
quetiapine both show moderate affinity for D1 and D2 dopamine
receptor binding (K i < 1µM). Additionally, quetiapine dissoci-
ates rapidly from D2 receptors, so it must be administered at
high dosages to exert an antipsychotic effect. It also exhibits good
extrapyramidial tolerability and a low capacity for up-regulation
at these receptors, which explains the low incidence of tardive
dyskinesia associated with it (40, 48).
At the level of the nigrostriatal and tuberoinfundibular
dopamine pathways, SERT seems to act as an inhibitory modulator
by means of 5-HT2A receptor stimulation. Quetiapine and nor-
quetiapine are 5-HT2A receptor antagonists (K i 100 and 48 nM,
respectively) (49), facilitating dopamine release along those path-
ways. PET studies have revealed higher 5-HT2A than D2 antag-
onism along said pathways (50), which explains why quetiapine
is not linked to hyperprolactinaemia and is well tolerated from
an extrapyramidal standpoint. Given that norquetiapine is more
Frontiers in Psychiatry | Neuropharmacology September 2013 | Volume 4 | Article 102 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
López-Muñoz and Álamo Antidepressant properties of norquetiapine
adept at blocking 5-HT2A than D2 receptors, its tolerability is
similar or even better than quetiapine’s.
Moreover, greater dopamine release by quetiapine and nor-
quetiapine not only improves its tolerability. Through various
mechanisms, dopamine release in the mesocortical pathway could
explain improved functioning in the prefrontal cortex (PFC) and
hippocampus, which, in addition to relieving schizophrenia’s neg-
ative and cognitive symptoms, contributes to the drug’s antide-
pressant impact. Effectively, dopamine deficit in the PFC could
explain some of the central symptoms of depression, such as anhe-
donia, social withdrawal, loss of motivation, and psychomotor
retardation (51).
Dopamine release in the PFC is mediated by a complicated
balance of several neurotransmitters and their receptors. As men-
tioned above, 5-HT2A receptor blockage produces a spike in
nigrostriatal and tuberoinfundibular dopamine levels, but also
facilitates mesocortical dopamine release.
Moreover, 5-HT2C receptor blockage eases cortical dopamine
release (52), but that effect is secondary to inhibition of GABAer-
gic interneurons in the brainstem (42). Thus, norquetiapine’s
affinity for this receptor is low (K i= 107 nM), but higher than
its affinity for many dopamine receptors. Still, quetiapine would
need concentrations 10 times higher (K i= 2450 nM) than nor-
quetiapine to block D2 receptors (49). Therefore, mesocortical
dopamine release, mediated by 5-HT2A blockage, is essentially due
to norquetiapine.
The NET transporter is responsible for dopamine reuptake in
the PFC, and norquetiapine inhibits that transporter, not quetiap-
ine, increasing dopamine levels in the frontal cortex and adding
to the antidepressant effect (49, 52). Since norquetiapine is not
formed in rodents, concomitant administration of quetiapine
and reboxetine, a norepinephrine reuptake inhibitor, resulted in
a synergistic increase in cortical dopamine output (53).
SEROTONERGIC FUNCTIONING
In addition to the ability of quetiapine and norquetiapine to
antagonize different SERT receptors, thereby easing dopamine
transmission, those agents also facilitate SERT transmission. In
effect, quetiapine, and to a greater extent its metabolite norqueti-
apine, facilitate serotonergic transmission by behaving as partial
agonists at 5-HT1A receptors. 5-HT1A receptors are associated with
antidepressant and anxiolytic effects in humans. Presynaptic 5-
HT1A receptors in the raphe nuclei control serotonergic neurons’
release, while those located in postsynaptic limbic and cortical
regions modulate serotonergic functioning. In fact, azapirones,
like buspirone and gepirone, are partial agonists at 5-HT1A recep-
tors whose anxiolytic and antidepressant properties have been
demonstrated in controlled clinical trials (54).
Norquetiapine has a high affinity for 5-HT1A receptors
(K i= 45 nM), similar to that of conventional 5-HT1A agonists
buspirone and gepirone (55) and 10 times greater than quetiap-
ine’s (K i= 430 nM). Moreover, in functional studies of GTPg-35s,
the metabolite was also more efficacious than quetiapine itself (75
vs. 47% of maximum SERT response) (49).
Hence, norquetiapine can bring about activation at post-
synaptic 5-HT1A receptors in the hippocampus (56), an area
of the brain altered by depression. This could spur neuron
regeneration in that area by increasing the release of nerve
growth factors like brain-derived neurotrophic factor (BDNF)
(57). Also, 5-HT1A receptor stimulation increases acetylcholine
release in the PFC, promoting synaptic plasticity linked to learn-
ing and memory (58). Norquetiapine’s effect as a partial agonist
of 5-HT1A receptors may contribute, at least in part, to que-
tiapine’s clinically demonstrated antidepressant and anxiolytic
action (59).
Norquetiapine also has a higher affinity for the 5-HT7 recep-
tor (K i= 76 nM) than quetiapine (K i= 307 nM). This receptor’s
involvement in depression and sleep-related, circadian rhythm dis-
orders has been experimentally documented (60). While no data
are available about 5-HT7 antagonists’ effects in humans, it is pos-
sible that norquetiapine’s 5-HT7 receptor antagonism contributes
to quetiapine’s antidepressant action (49).
As discussed above, quetiapine, and to a greater extent nor-
quetiapine, have antagonistic properties at 5-HT2A receptors. Use
of 5-HT2A antagonists has been proposed to treat insomnia, so
perhaps norquetiapine, which is also a potent H1 receptor antag-
onist, contributes to the highly sedative effects observed during
quetiapine treatment (49).
Norquetiapine has a high affinity (K i= 14 nM) for 5-HT2B
receptors (49). It is well-known that drugs that stimulate that par-
ticular receptor are closely tied to acute heart valve disease (61).
However, norquetiapine binds to said receptor purely as an antag-
onist, not as an agonist, ruling out the possibility that it would
cause valvular disease (49).
Some researchers have postulated that 5-HT2C receptor block-
age, paired with H1 histamine receptor blockage, is linked to
weight gain caused by treatment with antipsychotics (62, 63).
Since norquetiapine binds to 5-HT2C receptors (K i= 107 nM)
with much more potency than quetiapine (K i= 2502 nM), while
also blocking histamine receptors (K i= 3.5 nM), weight gain may
be primarily the fault of this metabolite (49).
NORADRENERGIC FUNCTIONING
Norquetiapine acts as a potent NET transporter inhibitor
(K i= 23 nM), while quetiapine does not actively inhibit said
transporter. Norquetiapine’s affinity for the NE transporter
(K i= 58 nM) is similar to that of certain other antidepressants
like nortriptyline, amitriptyline, and duloxetine (49). Quetiapine,
in contrast, cannot bind to the NET transporter. This differential
feature of norquetiapine versus quetiapine may have an impact on
antidepressant ability.
Also, norquetiapine increases noradrenergic functioning by
blocking presynaptic α2 receptors (K i= 237 nM) considerably
more than quetiapine (K i= 3630 nM) (49). 5-HT2A and 5-HT2C
antagonism promotes this increase in NET, which in turn raises
dopamine and NET levels in the PFC, as mentioned above (42, 49,
64, 65). By inhibiting the NET transporter, norquetiapine increases
dopamine levels in the PFC, because dopamine also employs the
NET transporter for reuptake (49, 52).
According to data collected in vivo, norquetiapine at dosages
as low as 0.1 mg/Kg displayed antidepressant activity in the tail
suspension test in mice (49).
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OTHER MECHANISMS INVOLVED IN THE ANTIDEPRESSANT EFFECT OF
QUETIAPINE
Other alternative, much less thoroughly studied mechanisms than
those involving monoamines may be at work in quetiapine’s anti-
depressant action. For example, stress and depression are known to
increase neurodegeneration, and antidepressants may counteract
that effect or undo it altogether. In experimental studies, que-
tiapine has been shown to prevent BDNF reduction as well as
chronic stress-related cellular degeneration in the hippocampus.
It has been postulate that these effects could improve some of the
symptoms and cognitive deficits implicated in depression (66).
Additionally, quetiapine has been observed to modulate the
activity of glutamate receptors to hypothetically restore them to
normal functioning. This would decrease the neurotoxicity caused
by an excess of the neurotransmitter glutamate (67).
Other authors have postulated that quetiapine may exert anti-
depressant effects by controlling inflammatory cytokines, cyto-
protective molecules, and the antioxidant effect, all of which are
mechanisms associated with the onset of depressive symptomatol-
ogy (68), though there is scarcely any experimental or clinical sup-
port for that hypothesis. Norquetiapine’s role in those mechanisms
has not yet been studied.
NORQUETIAPINE’S RECEPTOR BINDING TO BLAME FOR ADVERSE
EFFECTS
The receptor profiles of quetiapine and norquetiapine may explain
the adverse effects that often arise in treating depression. The abil-
ity of quetiapine (K i= 11 nM) and norquetiapine (K i= 3.5 nM)
to bind to H1 histamine receptors is associated with sedation,
hypnotic effects, increased appetite, and weight gain.
Blockage of α1 adrenergic receptors, which both quetiapine
and norquetiapine exhibit, is linked to orthostatic hypertension in
some patients. This is less true of quetiapine XR, which has fewer
plasmatic “peaks.”
Norquetiapine shows affinity for muscarine receptors, always
acting as an antagonist, especially at subtypes M1, M3, and M5.
This antagonism is 20–80 times stronger than what was observed
with quetiapine, so it is believed that adverse atropinic effects like
dry mouth, urine retention, mydriasis, increased intraocular pres-
sure, and hypothermia result from quetiapine’s active metabolite.
On the other hand, some researchers postulate that M3 receptor
antagonism is responsible, at least in part, for the onset of hyper-
glycemia and diabetes caused by antipsychotic treatment (69). It
would seem that most of these adverse effects following queti-
apine overdose (70) are due primarily to its active metabolite,
norquetiapine (49).
CONCLUSION
Quetiapine is a multifunctional drug endowed with antidepressant
properties through various mechanisms: noradrenergic, seroton-
ergic, and dopaminergic. Quetiapine displays clinically significant
efficacy in treating unipolar depression, both as a monotherapy
(off-label use; only in Australia and Canada is this an officially
approved indication) and as adjunctive therapy with antidepres-
sants in patients who respond unsatisfactorily or not at all to
antidepressants alone. Furthermore, quetiapine is the only drug
demonstrated to be effective at treating unipolar and bipolar
depression with no associated risk of veering into mania (68, 71).
The available data are sufficient to arrive at the conclusion that
quetiapine’s antidepressant activity is mediated, at least in part,
by the active metabolite norquetiapine, which selectively inhibits
NET reuptake, is a partial 5-HT1A receptor agonist, and acts as an
antagonist at presynaptic α2, 5-HT2C, and 5-HT7 receptors. Fur-
thermore, its active metabolite contributes to quetiapine’s profile
of undesirable effects because norquetiapine binds at H1 hista-
mine, α1 adrenergic, and muscarine receptors. Norquetiapine’s
activity profile is shared by no other known antipsychotic or
antidepressant drug (49).
Norquetiapine clearly exemplifies the case of an active metabo-
lite that, through metabolism, can make a drug originally intro-
duced as an antipsychotic, in this case quetiapine, become a useful
antidepressant agent.
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